IL5 and Increased total eosinophil count: Notably, anti-IL-5 biologics such as mepolizumab significantly reduce blood and lung eosinophilia in asthmatic patients but have no effect on the physiologic duodenal infiltration of eosinophils [41], which is, however, reduced by anti-Siglec-8 antibodies [42], suggesting that other IL-5-independent pro-survival mechanisms exist.